PARA vs SYRE · rev $5.0M vs $7.60B cap
PARA (PARA) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
PARA (PARA) common stock.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported PARA revenue for 2026-06-30 was $5.0M. Net income was -$13.4M. Revenue was up 84.3% from 2026-03-31 to 2026-06-30. PARA currently screens at market cap $0.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
PARA currently screens at market cap $0. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the PARA and SYRE stock pages for the full models.
Not investment advice.